These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 11683014)
21. [HIV infection: future perspective for a so-called fatal disease?]. von Overbeck J; Iten A Schweiz Med Wochenschr; 1997 Mar; 127(13):521-7. PubMed ID: 9190663 [TBL] [Abstract][Full Text] [Related]
22. How testing for HIV resistance influences therapeutic decision making. Analysis of a sample of 600 clinicians. Mascolini M; Wensing AM; Boucher CA IAPAC Mon; 2001 Mar; 7(3):85-90. PubMed ID: 11697306 [No Abstract] [Full Text] [Related]
25. To start or not to start? Learned J Posit Aware; 2001; 12(5):28-9. PubMed ID: 11688482 [No Abstract] [Full Text] [Related]
26. Arriving too soon: suggestions for the coming generation of "heavily treated" patients. Simmons P Res Initiat Treat Action; 2000 Sep; 6(3):5-6. PubMed ID: 11708166 [No Abstract] [Full Text] [Related]
28. When to start antiretroviral therapy? NA-ACCORD stimulates the debate. Gallant JE AIDS Read; 2009 Feb; 19(2):49-50, 61. PubMed ID: 19271328 [No Abstract] [Full Text] [Related]
29. [HIV infection. Virus resistance: development and prevention]. Link R; Miller V; Fätkenheuer G; Manegold C; Harrer T Med Monatsschr Pharm; 1999 Mar; 22(3):86-8. PubMed ID: 10223868 [No Abstract] [Full Text] [Related]
30. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750 [TBL] [Abstract][Full Text] [Related]
31. [HIV and antiretroviral therapy: in every 3rd patient a virus rebound takes place]. Kunde K Dtsch Med Wochenschr; 2000 Aug; 125(33):A10. PubMed ID: 11023348 [No Abstract] [Full Text] [Related]
32. Ongoing HIV dissemination during HAART. Grossman Z; Polis M; Feinberg MB; Grossman Z; Levi I; Jankelevich S; Yarchoan R; Boon J; de Wolf F; Lange JM; Goudsmit J; Dimitrov DS; Paul WE Nat Med; 1999 Oct; 5(10):1099-104. PubMed ID: 10502799 [No Abstract] [Full Text] [Related]
33. Antiretroviral rounds. Should we mess with success? J Watch AIDS Clin Care; 2009 Aug; 21(8):63-5. PubMed ID: 19795534 [No Abstract] [Full Text] [Related]
34. Pediatric antiretroviral therapy: from research to practice. Farley J; Vink P Pediatr AIDS HIV Infect; 1996 Feb; 7(1):9-13. PubMed ID: 11361479 [No Abstract] [Full Text] [Related]
35. Interleukin-2 clinical trials. Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495 [TBL] [Abstract][Full Text] [Related]
36. Stopping antiretroviral therapy in 'prematurely treated' HIV-1-infected children with full viral supression is safe. Reula ES; León-Leal JA; Leal M; Obando I; Muñoz-Fernández A AIDS; 2006 Jan; 20(2):307-9. PubMed ID: 16511434 [No Abstract] [Full Text] [Related]
37. [Four years without resistance--newer standard in HIV therapy]. Dtsch Med Wochenschr; 2003 May; 128(19):1075-6. PubMed ID: 12774798 [No Abstract] [Full Text] [Related]
38. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008). Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB; J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643 [No Abstract] [Full Text] [Related]